Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 3/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754317 | 0.88 | MAOA (0.37) | SPRLMNASMN1; SMN2L3MBTL1HCRTR1 | |
| SCHEMBL2744850 | 0.86 | LMNA (0.47) | LMNASMN1; SMN2PARP1ALDH1A1GAA | |
| SCHEMBL2743989 | 0.83 | LMNA (0.44) | LMNASMN1; SMN2PARP1ALDH1A1GAA | |
| SCHEMBL2743711 | 0.81 | SGPL1 (0.37) | MCHR1LMNASMN1; SMN2PARP1MAPT | |
| SCHEMBL2743709 | 0.81 | SGPL1 (0.37) | MCHR1LMNASMN1; SMN2PARP1MAPT | |
| SCHEMBL2744108 | 0.81 | SGPL1 (0.37) | MCHR1LMNASMN1; SMN2PARP1MAPT | |
| SCHEMBL2744471 | 0.80 | LMNA (0.37) | SPRLMNASMN1; SMN2L3MBTL1HCRTR1 | |
| SCHEMBL13592446 | 0.80 | LMNA (0.39) | LMNASMN1; SMN2L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL4400020 | 0.77 | MAOB (0.45) | L3MBTL1PARP1TNK1DGAT1 | |
| SCHEMBL2743838 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2L3MBTL1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | claimed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | claimed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | MCHR1 4753/4885SPR 4777/4885LMNA 2876/4885 |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K3, IP6K2 | MCHR1 4777/4885SPR 4834/4885LMNA 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.